[go: up one dir, main page]

WO2001023088A1 - Catalyst for asymmetric transfer hydrogenation - Google Patents

Catalyst for asymmetric transfer hydrogenation Download PDF

Info

Publication number
WO2001023088A1
WO2001023088A1 PCT/NL2000/000701 NL0000701W WO0123088A1 WO 2001023088 A1 WO2001023088 A1 WO 2001023088A1 NL 0000701 W NL0000701 W NL 0000701W WO 0123088 A1 WO0123088 A1 WO 0123088A1
Authority
WO
WIPO (PCT)
Prior art keywords
enantiomerically enriched
catalyst according
catalyst
ligand
sulphur
Prior art date
Application number
PCT/NL2000/000701
Other languages
French (fr)
Inventor
Danielle Geertruida Irene Petra
Paulus Clemens Jozef Kamer
Petrus Wilhelmus Nicolaas Maria Van Leeuwen
Johannes Gerardus De Vries
Hans Egbert Schoemaker
Original Assignee
Dsm N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm N.V. filed Critical Dsm N.V.
Priority to AU79721/00A priority Critical patent/AU7972100A/en
Priority to EP00970322A priority patent/EP1227883A1/en
Priority to JP2001526290A priority patent/JP2003510180A/en
Publication of WO2001023088A1 publication Critical patent/WO2001023088A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/226—Sulfur, e.g. thiocarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60—Reduction reactions, e.g. hydrogenation
    • B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/643—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of R2C=O or R2C=NR (R= C, H)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/822—Rhodium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/827—Iridium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84—Metals of the iron group
    • B01J2531/845—Cobalt
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the invention relates to a catalyst for asymmetrical transfer hydrogenation on the basis of a transition metal compound and a nitrogen-containing enantiomerically enriched ligand.
  • the invention also relates to various processes for the preparation of enantiomerically enriched compounds using the catalyst according to the invention.
  • Asymmetrical transfer hydrogenation is a method for the preparation of an enantiomerically enriched compound in which the presence of a transition metal catalyst containing an enantiomerically enriched ligand ensures that the double bond of a prochiral compound is asymmetrically reduced through hydrogen transfer with a hydrogen-donating organic compound. This is taken to mean at least that in the reaction product an excess of one of the enantiomers of the compound prepared is present. This excess will hereinafter be referred to as "enantiomeric excess" or e.e. (as determined by capillary GLC analysis over a chiral cycloSil-B column) .
  • Such a catalyst is known from EP 0-916-637.
  • the nitrogen-containing enantiomerically enriched ligand is a diamine, an amino alcohol or an aminophosphine compound and the transition metal is chosen from group VIII of the periodic system, this preferably being ruthenium.
  • 0-916-637 particularly the catalysts that contain amino-alcohol ligands, is that actually they are stable enough only when alcohols are used as the hydrogen donor.
  • An acceptable enantiomeric excess is achieved only if a huge excess of the hydrogen-donating alcohol is added. This is disadvantageous since it results in relatively low space time yields being obtained using production equipment of a given size and since the huge excess must be separated and purified for reuse, which adversely affects process economics.
  • a further disadvantage is that the known catalysts, particularly the catalysts that contain diamine and the aminophosphine ligands, often have a too low activity and are not enantioselective enough as a result of which the enantiomerically enriched compound obtained with it has a too low enantiomeric excess (e.e.).
  • the aim of the invention therefore is to provide a catalyst for asymmetrical transfer hydrogenation that does not have the above-mentioned drawbacks .
  • the transition metal is iridium, ruthenium, rhodium or cobalt and the enantiomerically enriched ligand contains sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms.
  • the transition metal in the catalyst is iridium.
  • the iridium catalyst according to the invention has been found to give rise to a very good enantiomeric excess and conversion besides being very stable.
  • a hydrogen donor that effects irreversible transfer hydrogenation such as formic acid, partially unsaturated heterocycles and partially unsaturated hydrocarbons
  • a hydrogen donor that effects irreversible transfer hydrogenation such as formic acid, partially unsaturated heterocycles and partially unsaturated hydrocarbons
  • the reaction can take place in the air rather than under argon .
  • the enantiomerically enriched ligand in the catalyst according to the invention has a general molecular structure as indicated in the formula where Ri up to and including R 7 can each in principle be any substituent, it being understood that Ri cannot be hydrogen, that n is 0 or 1 (thioether or sulphoxide) , that one or both of Re and R 7 are hydrogen (secondary or primary amine) and that there must be at least one chiral centre in the molecule. Further, Ri up to and including R 7 can for instance be a hydrogen
  • Each of the substituents Ri up to and including R 7 can form a ring together with other substituents.
  • the sulphur and/or the nitrogen themselves may also form part of a ring.
  • the sulphur can be bound to the nitrogen via two or more carbon atoms.
  • X can be nothing, so that the sulphur- containing group and the amine are vicinal, but may also contain one or more carbon or heteroatoms, in a ring or not. Examples are methionine- derived ligands with three carbon atoms between the nitrogen and the sulphur. If heteroatoms are present between the sulphur and the nitrogen group, these are preferably separated from the sulphur and the nitrogen by two or more carbon atoms.
  • the sulphur is bound to the nitrogen via two carbon atoms. Such a catalyst has been found to have a higher activity.
  • the nitrogen in the enantiomerically enriched ligand is preferably an amine group.
  • the amine group is substituted at most once (secondary amine) , or, preferably, not substituted which means that R 6 or R 7 is hydrogen and that more preferably Re and R are both hydrogen.
  • the sulphur has the form of a thioether or a sulphoxide (n is 0 or 1) .
  • the sulphur is substituted with a group containing at least one carbon.
  • the sulphur is substituted with a substituted or non-substituted alkyl, (hetero)aryl or (hetero) aralkyl group. It is possible for a heteroatom to be present in the aromatic ring.
  • suitable sulphur substituents are isopropyl, cyclohexyl, phenyl, benzyl, 2-phenethyl, naphthyl, thiophene and furan. This increases the reactivity and the e.e.
  • the ligand in the catalyst according to the invention must be enantiomerically enriched. This is taken to mean that one of the enantiomers of the ligand is present in the catalyst in an excess.
  • the enantiomeric excess is more than 90%, more preferably more than 95% and most preferably more than 99%.
  • the chiral centre in the enantiomerically enriched active ligand in the catalyst according to the invention may in principle be present at various places, but preferably lies beside or near the nitrogen- containing group or the thioether group. In one embodiment the chiral centre is located at the carbon to which the nitrogen-containing group is bound.
  • Such an enantiomerically enriched ligand can simply be derived from enantiomerically enriched cysteine (Table 1, ligand 1) . This is an amino acid that is widely available and therefore inexpensive.
  • the carboxylic acid group is reduced to an alcohol group (Table 1, ligand 2) .
  • This embodiment has a higher activity.
  • Preferably, however, of the two or more carbon atoms that bind the sulphur to the nitrogen at least the carbon bound to the sulphur is chiral. This has the advantage that a higher e.e. is obtained.
  • the enantiomerically enriched ligand in the catalyst according to the invention has two or more chiral centres.
  • the enantiomerically enriched ligand is a sulphoxide, with one of the two or more chiral centres being the sulphur of the sulphoxide (Table 1, ligand 3) .
  • This ligand is particularly attractive as it can be prepared in a simple manner by oxidation, for instance with peroxide, of an inexpensive starting material such as cysteine or the alcohol derived from it (Table 1, ligand 2) , so that the ligand is very inexpensive.
  • the enantiomerically enriched ligand is a thioether in which the carbon atoms to which the thioether and the amino group are bound are both chiral (for instance Table 1, ligands 4, 5 and 6) .
  • These catalysts have a high activity and give rise to a very high enantioselectivity.
  • the enantiomerically enriched ligands in the catalyst according to the invention can also very suitably be prepared by converting an enantiomerically enriched aziridine compound with a thiol compound. This reaction proceeds via a stereoselective ring opening so that an enantiomerically enriched thioether compound is obtained according to the following reaction scheme: (aziridine)
  • the aziridine can be prepared in a simple manner by dehydration of an enantiomerically enriched vicinal amino alcohol, for instance with triphenylphosphine and DIAD (di-isopropyl azodicarboxylate) .
  • Enantiomerically enriched vicinal amino alcohols are often widely available and relatively inexpensive. Examples include ephedra-alkaloids, for instance ephedrine and norephedrine, and reduced amino acids.
  • the enantiomerically enriched ligand is derived from an aziridine, itself derived from an enantiomerically enriched vicinal amino alcohol, by reaction with a thiol compound.
  • An enantiomerically enriched ligand with a single chiral centre at the carbon beside the sulphur can for instance be prepared by conversion with a thiol compound of an aziridine derived from a reduced phenylglycine .
  • the ligand has two chiral centres because the two carbons of the aziridine ring are substituted, the ligand in the catalyst for instance being 2-amino-l- benzylthioether-1, 2-diphenylethane.
  • This ligand has a chiral centre at the carbon beside the sulphur and on the carbon beside the nitrogen.
  • a catalyst with this ligand has a very good activity and gives rise to a very good enantioselectivity.
  • the catalyst based on the transition metal compound and the enantiomerically enriched ligand can be applied in the form of separate components, one of which is the transition metal compound while another one is the enantiomerically enriched ligand, or as a complex containing the transition metal compound and the enantiomerically enriched ligand.
  • X is an anion such as, for instance, hydride, halide, carboxylate, alkoxy, hydroxy or tetrafluoroborate;
  • S is a so-called spectator ligand, a neutral ligand that is difficult to exchange, for instance an aromatic compound or an olefin, in particular a diene.
  • aromatic compounds are: benzene, toluene, xylene, cumene, cymene, naphthalene, anisole, chlorobenzene, indene, dihydroindene, tetrahydronaphthalene, cholic acid, benzoic acid and phenylglycine.
  • dienes are norbornadiene, 1, 5-cyclooctadiene and 1, 5-hexadiene.
  • L is a neutral ligand, which can relatively easily be exchanged with other ligands, and is for instance a nitrile or a co-ordinating solvent, in particular acetonitrile, dimethylsulphoxide (DMSO) , methanol, water, tetrahydrofuran, dimethylformamide, pyridine and N-methylpyrrolidinone.
  • a neutral ligand which can relatively easily be exchanged with other ligands, and is for instance a nitrile or a co-ordinating solvent, in particular acetonitrile, dimethylsulphoxide (DMSO) , methanol, water, tetrahydrofuran, dimethylformamide, pyridine and N-methylpyrrolidinone.
  • DMSO dimethylsulphoxide
  • Suitable transition metal compounds are:
  • the transition metal compound is [Ir (COD) Cl] 2 .
  • the invention also relates to a process for the preparation of the catalyst according to the invention as described above, which involves the addition to a catalyst precursor, which contains the transition metal, an anion and a spectator ligand that is difficult to exchange, of a nitrogen-containing enantiomerically enriched ligand containing sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms.
  • the catalyst can be prepared before it is used as an asymmetrical transfer hydrogenation catalyst or it can be formed in situ just before or during use, optionally in the presence of the reagents to be converted with the catalyst.
  • catalysts according to the invention can be made to be readily soluble in water or highly polar solvents .
  • the catalysts of the invention can be rendered water-soluble by introducing water-soluble groups in the ligand, for instance, salts of carboxylic acids, salts of sulphonic acids and salts of phosphoric acids. Another possibility is the introduction of a trialkylammonium salt or a tetraalkylammonium salt in the ligand.
  • a third group of substituents that can be introduced on the ligand are the neutral polar groups of which there may be various present in the molecule, such as alcohols and sulphoxides .
  • Another way of rendering the catalyst water-soluble is to use bifunctional counter ions for the metal, for instance biscarboxylic acids, bisphosphates and bissulphonates .
  • One of the two acid groups then serves as counter ion for the metal, while the other acid group is present as the salt of for instance sodium, potassium or lithium and imparts water solubility.
  • the advantage of a water-soluble catalyst is that the transfer hydrogenation reaction can be carried out in a two-phase system, for instance a (more) polar aqueous phase and a (less polar) organic phase such as water/organic solvent, with the catalyst and the reducing agent being in the aqueous phase and the starting material and the product in the organic phase.
  • a mixture of triethylamine and formic acid can also be chosen as the more polar phase.
  • An example is the reduction of ketones in a two-phase system, with the more polar phase comprising an azeotropic mixture of triethylamine and formic acid, and the less polar phase comprising the ketone and the alcohol formed therefrom, optionally in the presence of a non-water-miscible solvent.
  • the product can simply be separated by phase separation and the more polar phase can, after addition of extra formic acid, be reused in the reduction of a new batch of ketone.
  • Another example of a more polar phase is ionic liquids. Examples of these are salts of imidazole such as l-hexyl-3-methyl-imidazolium salts or N-alkyl pyridinium salts. These compounds are characterized by the fact that they are liquids at room temperature.
  • the invention also relates to a process for the preparation of an enantiomerically enriched compound from the corresponding prochiral compound via catalytic asymmetrical transfer hydrogenation in the presence of a hydrogen donor and the catalyst according to the invention as described above.
  • the process can for instance very suitably be used in the preparation of enantiomerically enriched alcohols, hydrazines or amines starting from the corresponding prochiral ketones and, respectively, hydrazones, oxime derivatives or imines .
  • the catalysts of the invention can also advantageously be used for the kinetic resolution of carbonyl compounds - e.g. ketones or aldehydes - or imines, oximes or hydrazones which already contain at least one chiral centre elsewhere in the molecule and are present in racemic form. Reduction of the carbonyl compounds, imines, oximes or hydrazones then most preferably takes place only in one of the two enantiomeric forms. By terminating the reaction when approximately 50% conversion is achieved, the ketone (aldehyde, imine, oxime, hydrazone) can be recovered substantially in the one enantiomeric form; the other enantiomer has then substantially been converted to the corresponding alcohol, amine or hydrazine.
  • carbonyl compounds e.g. ketones or aldehydes - or imines, oximes or hydrazones which already contain at least one chiral centre elsewhere in the molecule and are present in racemic form. Reduction of the carbony
  • the catalysts of the invention can also be advantageously used for the kinetic resolution of a racemic alcohol by oxidation in the presence of the catalyst according to the invention.
  • this reaction it is higly preferred for only one of the enantiomers of the alcohol to be oxidised, so that after about 50% conversion a mixture has formed of the alcohol, consisting substantially of a single enantiomer, and the corresponding ketone, which has been formed from the other enantiomer.
  • Suitable oxidants for this are ketones or aldehydes, for instance acetone or chloral (hydrate) .
  • the catalysts of the invention can also be advantageously used for the desymmetrization of meso diols by oxidation in the presence of the catalyst according to the invention.
  • the meso diol is oxidised to a hydroxy ketone in a stereoselective manner such that the product hydroxy ketone consists substantially of a single enantiomer.
  • the catalysts of the invention can also in principle be advantageously used for the preparation of a ketone in an enantiomeric excess from a racemic alcohol which contains a further chiral racemic centre that is not bound to the OH group by oxidation in the presence of the catalyst according to the invention so that after about 50% conversion a mixture has formed of the enantiomerically enriched ketone (formed substantially from one of the two absolute configurations at the chiral centre not bound to the OH group) and two enantiomerically enriched diastereomers of the alcohol, consisting substantially of the other absolute configuration at the chiral centre not bound to the OH group.
  • the catalyst according to the invention can in principle be used to selectively oxidise one of the two diastereomers which are epimeric at the carbon bound to the OH group, so that after about 50% conversion a mixture has formed of the enantiomerically enriched ketone (formed substantially from one of the two enantiomerically enriched epimers) and the diastereomerically enriched alcohol (consisting substantially of the other enantiomerically enriched epimer) .
  • the invention also relates to a process for the preparation of an enantiomerically enriched compound with two or more chiral, non racemic centres in which a chiral, non racemic ketone, imine, oxime or hydrazone is reduced in the presence of a catalyst according to the invention.
  • a chiral, non racemic ketone, imine, oxime or hydrazone is reduced in the presence of a catalyst according to the invention.
  • the ketone is fully reduced to a compound with substantially only one relative configuration between the existing chiral, non racemic centre (s) and the new chiral, non racemic centre.
  • prochiral ketones use can for instance be made of prochiral ketones of the general formula:
  • R and R' are not the same and each independently represent an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms or together they form a ring along with the carbonyl C-atom to which they are bound, it being possible for R and R' to also contain one or more heteroatoms or functional groups.
  • prochiral ketones include acetophenone, 1- acetonaphthone, 2-acetonaphthone, 3-quinuclidinone, 2- methoxycyclohexanone, l-phenyl-2-butanone, benzyl- isopropyl ketone, benzyl acetone, cyclohexyl-methyl ketone, tert-butyl-methyl ketone, tert-butyl-phenyl ketone, isopropyl-phenyl ketone, ethyl- (n-propyl) ketone, o, m or p-methoxy acetophenone, o, m or p- (fluoro-, chloro-, bromo- or iodo-) acetophenone, o, m or p-cyano-acetophenone, o, m or p-nitro-acetophenone, 2-acetylfluoro-
  • R, R' and R" for instance each independently represent an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms or form a ring together with the atoms to which they are bound, it being possible for R , R' and R" to also contain one or more heteroatoms and functional groups, and R" may in addition be a group to be split off.
  • Suitable prochiral imines may be prepared from the above-described ketones and an alkyl amine, aralkyl amine or aryl amine or an amino acid derivative, for instance an amino acid amide, an amino acid ester, a peptide or a polypeptide.
  • alkyl amines, aralkyl amines and aryl amines are a benzyl amine, for instance benzyl amine, or an o-, m- or p- substituted benzyl amine, an ⁇ -alkyl benzyl amine, a naphthyl amine, for instance naphthyl amine, a l-,2-,3- ,4-, 6-, 7-, 8- or 9-substituted naphthyl amine and a 1-(1- naphthyl ) alkyl amine or a 1- (2-naphthyl) alkyl amine.
  • Suitable imines are for instance N- (2-ethyl-6- methylphenyl ) -1-methoxy-acetonimine, 5, 6-difluoro-2- methyl-1, 4-benzoxazine, 2-cyano-l-pyrroline, 2- ethyoxycarbonyl-1-pyrroline, 2-phenyl-l-pyrroline, 2- phenyl-3 , 4, 5, 6-tetrahydropyridine and 3 , 4-dihydro-6, 7- dimethoxy-1-methyl-isoquinoline; oximes or hydrazones of the general formula
  • X contains a heteroatom and represents NH, NR or 0, for instance, with R representing an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms .
  • Ri and R 2 each independently represent an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms, or form a ring with each other or with R 3 and the atoms to which they are bound, which groups may also contain one or more heteroatoms and/or functional groups.
  • R 3 is H or an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms, which groups may also contain one or more heteroatoms and/or functional groups; and in the case of a hydrazone it is H, an alkyl, aryl, alkenyl, alkynyl, acyl, phosphonyl or sulphonyl group with 0-20 C-atoms, which groups may also contain one or more heteroatoms and/or functiona1 groups .
  • the process according to the invention is carried out in the presence of one or more hydrogen donors, which in the framework of this invention are understood to mean compounds that can in any way transfer hydrogen to the substrate, for instance thermally or catalytically .
  • suitable hydrogen donors that can be used are aliphatic or aromatic alcohols, in particular secondary alcohols with 1-10 C-atoms, for instance 2-propanol and cyclohexanol, acids, for instance formic acid, H 3 P0 2 , H 3 P0 3 and salts thereof, partially unsaturated hydrocarbons, partially unsaturated heterocyclic compounds, hydroquinone or reducing sugars.
  • 2-propanol or formic acid is used.
  • the molar ratio of substrate to hydrogen donor preferably lies between 1:1 and 1:100.
  • asymmetrical transfer hydrogenation use is preferably made of a molar ratio of metal present in the transition metal compound to substrate of between 1:10 and 1:1,000,000, in particular between 1:100 en 1:100,000.
  • the temperature at which the asymmetrical transfer hydrogenation is carried out in general is a compromise between the reaction velocity on the one hand and the degree of racemisation on the other, and preferably lies between -20 and 100°C, in particular between 0 and 60°C.
  • the asymmetrical transfer hydrogenation can in principle be carried out in an oxygen-containing atmosphere; preferably, however, the asymmetrical transfer hydrogenation is carried out in an inert atmosphere, for instance under nitrogen.
  • solvent any solvent can be used that is inert in the reaction mixture.
  • a solvent is used that also serves as hydrogen donor, for instance 2-propanol.
  • a water-soluble catalyst is used.
  • the catalyst for the asymmetrical transfer hydrogenation can if desired be activated by hydrogenation with hydrogen or by treatment with a base, for instance an alkali (alkaline earth) compound, for instance an alkali (alkaline earth) hydroxide, an alkali (alkaline earth) carboxylate or an alkali (alkaline earth) alkoxide with 1-20 C-atoms, as alkali metal for instance Li, Na or K being used and as alkaline earth metal for instance Mg or Ca.
  • a base for instance an alkali (alkaline earth) compound, for instance an alkali (alkaline earth) hydroxide, an alkali (alkaline earth) carboxylate or an alkali (alkaline earth) alkoxide with 1-20 C-atoms, as alkali metal for instance Li, Na or K being used and as alkaline earth metal for instance Mg
  • Suitable bases are for instance sodium hydroxide, potassium hydroxide, potassium-t-butoxide and magnesium methoxide.
  • the molar ratio of metal to the enantiomerically enriched ligand is preferably chosen to be between 2:1 and 1:10, preferably between 1 : 1 and 1:6.
  • a hydrogen donor that effects irreversible transfer hydrogenation.
  • a hydrogen donor is formic acid or a formic acid salt, preferably in combination with triethylamine.
  • the formic acid decomposes and carbon dioxide gas is formed in the transfer hydrogenation reaction and, this being outside the reaction equilibrium, the reaction runs to completion.
  • a higher substrate concentration can be chosen compared to an alcohol such as isopropanol.
  • the concentration of prochiral compound is at least 0.2, more preferably at least 0.5 and even more preferably at least 0.7 mol per litre of the hydrogen donor.
  • the catalyst according to the invention has been found to be stable, in particular when iridium is used as the transition metal .
  • the reaction with formic acid as hydrogen donor proceeds as follows: a solution of [IrCl(COD)] 2 (0.01 mmol, 6.7 mg) as catalyst precursor (COD is cyclooctadiene) , 0.05 mmol ligand and 4 mmol acetophenone as substrate was heated at 65°C for 30 min under argon. The argon supply was stopped and 3 ml of a 5/2 azeotropic mixture of formic acid (as hydrogen donor) and triethylamine was added in air. The reaction proceeded at 60 °C in an open vessel for the indicated time.
  • the reaction with 2-propanol as hydrogen donor proceeds as follows: the solution of [IrCl(COD)] 2 (0.01 mmol, 6.7 mg) , 0.05 mmol of the ligand and 5 ml 2- propanol were heated at 80°C for 30 min. After cooling to room temperature the mixture was diluted with 33.75 ml 2-propanol and 4 mmol acetophenone and t-BuOK (1.25 ml, 0.1M in propan-2-ol, 0.125 mmol) . The reaction was carried out at room temperature under argon for the indicated time.
  • the enantiomeric excess of the 1-phenethyl alcohol formed was determined by means of capillary GLC using a Carlo Erba GC 6000 Vega 2 with a 25 m Cyclosil-B (chiral) column.
  • the enantiomeric excess is defined as ( ( [R] - [S]) / ([R] + [S]))*100%, where [R] and [S] are the concentrations of the R enantiomer and the S enantiomer.
  • the conversion expressed as the percentage of acetophenone converted in one hour, was determined by means of GLC.
  • the optical rotation was determined using a Perkin-Elmer 241 automatic polarimeter.
  • substrate is 1-naphthyl-methyl ketone
  • substrate is phenyl-ethyl ketone
  • catalyst precursor is [Ru(p-Cy)Cl 2 ] 2
  • catalyst precursor is [Rh(COD)Cl] 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

The invention relates to a catalyst for asymmetrical transfer hydrogenation on the basis of a transition metal compound and a nitrogen-containing enantiomerically enriched ligand. The invention also relates to various processes for the preparation of enantiomerically enriched compounds using the catalyst according to the invention. In the catalyst according to the invention the transition metal is iridium, ruthenium, rhodium or cobalt and the enantiomerically enriched ligand contains sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms. Surprisingly, it has been found that with the catalyst according to the invention a high conversion in a good enantiomeric excess of the enantiomerically enriched compound can be obtained. It has been found, in addition, that the catalyst with iridium as metal is also very stable in formic acid, so that formic acid can be used as the hydrogen donor, making the reaction irreversible and thereby allowing it to run to completion so that higher substrate concentrations can be used.

Description

CATALYST FOR ASYMMETRICAL TRANSFER HYDROGENATION
The invention relates to a catalyst for asymmetrical transfer hydrogenation on the basis of a transition metal compound and a nitrogen-containing enantiomerically enriched ligand. The invention also relates to various processes for the preparation of enantiomerically enriched compounds using the catalyst according to the invention.
Asymmetrical transfer hydrogenation is a method for the preparation of an enantiomerically enriched compound in which the presence of a transition metal catalyst containing an enantiomerically enriched ligand ensures that the double bond of a prochiral compound is asymmetrically reduced through hydrogen transfer with a hydrogen-donating organic compound. This is taken to mean at least that in the reaction product an excess of one of the enantiomers of the compound prepared is present. This excess will hereinafter be referred to as "enantiomeric excess" or e.e. (as determined by capillary GLC analysis over a chiral cycloSil-B column) . The general advantage of such an asymmetrical transfer hydrogenation, for instance compared with reduction with molecular hydrogen, is that this reaction can take place under relatively mild conditions as regards temperature and pressure while the yield is relatively high and the byproduct content low, so that the production costs can be low. In practice, this asymmetrical transfer hydrogenation is often employed for the preparation of enantiomerically enriched alcohols from prochiral ketones .
Such a catalyst is known from EP 0-916-637. In this known catalyst the nitrogen-containing enantiomerically enriched ligand is a diamine, an amino alcohol or an aminophosphine compound and the transition metal is chosen from group VIII of the periodic system, this preferably being ruthenium. The drawback of the known catalysts from EP
0-916-637, particularly the catalysts that contain amino-alcohol ligands, is that actually they are stable enough only when alcohols are used as the hydrogen donor. This poses an inherent problem in the reduction of ketones in that the enantiomeric purity is often too low due to the reversibility of the transfer hydrogenation reaction and, in addition, the chemical similarity of the hydrogen donor alcohol and the enantiomerically enriched alcohols formed. An acceptable enantiomeric excess is achieved only if a huge excess of the hydrogen-donating alcohol is added. This is disadvantageous since it results in relatively low space time yields being obtained using production equipment of a given size and since the huge excess must be separated and purified for reuse, which adversely affects process economics. A further disadvantage is that the known catalysts, particularly the catalysts that contain diamine and the aminophosphine ligands, often have a too low activity and are not enantioselective enough as a result of which the enantiomerically enriched compound obtained with it has a too low enantiomeric excess (e.e.).
The aim of the invention therefore is to provide a catalyst for asymmetrical transfer hydrogenation that does not have the above-mentioned drawbacks .
This aim is achieved according to the invention in that the transition metal is iridium, ruthenium, rhodium or cobalt and the enantiomerically enriched ligand contains sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms.
Surprisingly, it has been found that very good results can be obtained with the catalyst according to the invention. Here and hereinafter this is taken to mean in particular a rapid and high conversion to a good enantiomeric excess (e.e.) of the enantiomerically enriched compound. Preferably, the transition metal in the catalyst is iridium. With this, very good results are obtained. The iridium catalyst according to the invention has been found to give rise to a very good enantiomeric excess and conversion besides being very stable. Surprisingly, it has also been found to be stable in formic acid, so that formic acid can also be used as the hydrogen donor. Since formic acid is converted to carbon dioxide gas in the reduction, transfer hydrogenation with this species is irreversible. In general, the use of a hydrogen donor that effects irreversible transfer hydrogenation (such as formic acid, partially unsaturated heterocycles and partially unsaturated hydrocarbons) is most advantageous since this allows the reaction to run to completion, thereby allowing the use of a much higher substrate concentration than when an alcohol is the hydrogen donor. Moreover, the irreversible nature of the reaction prevents racemization of the product. A further advantage of the specific case of formic acid/trialkylamine compared to alcohol as the hydrogen donor is that the reaction can take place in the air rather than under argon .
The enantiomerically enriched ligand in the catalyst according to the invention has a general molecular structure as indicated in the formula
Figure imgf000005_0001
where Ri up to and including R7 can each in principle be any substituent, it being understood that Ri cannot be hydrogen, that n is 0 or 1 (thioether or sulphoxide) , that one or both of Re and R7 are hydrogen (secondary or primary amine) and that there must be at least one chiral centre in the molecule. Further, Ri up to and including R7 can for instance be a hydrogen
(except for Ri) , an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms, or a group containing one or more heteroatoms, e.g. 0, N, P, or S, or functional groups. Each of the substituents Ri up to and including R7 can form a ring together with other substituents. The sulphur and/or the nitrogen themselves may also form part of a ring.
In general, the sulphur can be bound to the nitrogen via two or more carbon atoms. X can be nothing, so that the sulphur- containing group and the amine are vicinal, but may also contain one or more carbon or heteroatoms, in a ring or not. Examples are methionine- derived ligands with three carbon atoms between the nitrogen and the sulphur. If heteroatoms are present between the sulphur and the nitrogen group, these are preferably separated from the sulphur and the nitrogen by two or more carbon atoms. Preferably, in the catalyst according to the invention the sulphur is bound to the nitrogen via two carbon atoms. Such a catalyst has been found to have a higher activity. The nitrogen in the enantiomerically enriched ligand is preferably an amine group. With a view to obtaining a good activity and enantioselectivity the amine group is substituted at most once (secondary amine) , or, preferably, not substituted which means that R6 or R7 is hydrogen and that more preferably Re and R are both hydrogen.
In the catalyst according to the invention the sulphur has the form of a thioether or a sulphoxide (n is 0 or 1) . The sulphur is substituted with a group containing at least one carbon. Preferably, the sulphur is substituted with a substituted or non-substituted alkyl, (hetero)aryl or (hetero) aralkyl group. It is possible for a heteroatom to be present in the aromatic ring. Examples of suitable sulphur substituents are isopropyl, cyclohexyl, phenyl, benzyl, 2-phenethyl, naphthyl, thiophene and furan. This increases the reactivity and the e.e.
For a good enantioselective transfer hydrogenation the ligand in the catalyst according to the invention must be enantiomerically enriched. This is taken to mean that one of the enantiomers of the ligand is present in the catalyst in an excess. Preferably, the enantiomeric excess is more than 90%, more preferably more than 95% and most preferably more than 99%.
The chiral centre in the enantiomerically enriched active ligand in the catalyst according to the invention may in principle be present at various places, but preferably lies beside or near the nitrogen- containing group or the thioether group. In one embodiment the chiral centre is located at the carbon to which the nitrogen-containing group is bound. Such an enantiomerically enriched ligand can simply be derived from enantiomerically enriched cysteine (Table 1, ligand 1) . This is an amino acid that is widely available and therefore inexpensive. Preferably, the carboxylic acid group is reduced to an alcohol group (Table 1, ligand 2) . This embodiment has a higher activity. Preferably, however, of the two or more carbon atoms that bind the sulphur to the nitrogen at least the carbon bound to the sulphur is chiral. This has the advantage that a higher e.e. is obtained.
A particularly high e.e. is achieved if the enantiomerically enriched ligand in the catalyst according to the invention has two or more chiral centres. In a preferred embodiment of this catalyst the enantiomerically enriched ligand is a sulphoxide, with one of the two or more chiral centres being the sulphur of the sulphoxide (Table 1, ligand 3) . This ligand is particularly attractive as it can be prepared in a simple manner by oxidation, for instance with peroxide, of an inexpensive starting material such as cysteine or the alcohol derived from it (Table 1, ligand 2) , so that the ligand is very inexpensive. In another preferred embodiment of the catalyst in which the ligand has two or more chiral centres the enantiomerically enriched ligand is a thioether in which the carbon atoms to which the thioether and the amino group are bound are both chiral (for instance Table 1, ligands 4, 5 and 6) . These catalysts have a high activity and give rise to a very high enantioselectivity.
The enantiomerically enriched ligands in the catalyst according to the invention can also very suitably be prepared by converting an enantiomerically enriched aziridine compound with a thiol compound. This reaction proceeds via a stereoselective ring opening so that an enantiomerically enriched thioether compound is obtained according to the following reaction scheme:
Figure imgf000008_0001
(aziridine)
R,SH
Figure imgf000008_0002
This method has the further advantage that the aziridine can be prepared in a simple manner by dehydration of an enantiomerically enriched vicinal amino alcohol, for instance with triphenylphosphine and DIAD (di-isopropyl azodicarboxylate) . Enantiomerically enriched vicinal amino alcohols are often widely available and relatively inexpensive. Examples include ephedra-alkaloids, for instance ephedrine and norephedrine, and reduced amino acids. Preferably, therefore, in the catalyst according to the invention the enantiomerically enriched ligand is derived from an aziridine, itself derived from an enantiomerically enriched vicinal amino alcohol, by reaction with a thiol compound. An enantiomerically enriched ligand with a single chiral centre at the carbon beside the sulphur can for instance be prepared by conversion with a thiol compound of an aziridine derived from a reduced phenylglycine . In an embodiment that is more preferred the ligand has two chiral centres because the two carbons of the aziridine ring are substituted, the ligand in the catalyst for instance being 2-amino-l- benzylthioether-1, 2-diphenylethane. This ligand has a chiral centre at the carbon beside the sulphur and on the carbon beside the nitrogen. A catalyst with this ligand has a very good activity and gives rise to a very good enantioselectivity.
It has been found that in the case of a catalyst in which the ligand has two or more chiral centres (diastereomers) and in which the ligands form a diastereomeric mixture, asymmetrical transfer hydrogenation can take place if at least one of the diastereomers is enantiomerically enriched. Preferably, however, in that case too a single enantiomer of a single diastereomer is used to obtain the highest possible e.e.
The catalyst based on the transition metal compound and the enantiomerically enriched ligand can be applied in the form of separate components, one of which is the transition metal compound while another one is the enantiomerically enriched ligand, or as a complex containing the transition metal compound and the enantiomerically enriched ligand.
For the transition metal compound, use is preferably made of a catalyst precursor of the general formula
MnXpSqLr
where : n is 1,2,3,4.... ; p, q and r each independently represent 0,1,2,3,4...; M is a transition metal ruthenium, iridium, rhodium or cobalt, most preferably iridium; X is an anion such as, for instance, hydride, halide, carboxylate, alkoxy, hydroxy or tetrafluoroborate; S is a so-called spectator ligand, a neutral ligand that is difficult to exchange, for instance an aromatic compound or an olefin, in particular a diene. Examples of aromatic compounds are: benzene, toluene, xylene, cumene, cymene, naphthalene, anisole, chlorobenzene, indene, dihydroindene, tetrahydronaphthalene, cholic acid, benzoic acid and phenylglycine. Examples of dienes are norbornadiene, 1, 5-cyclooctadiene and 1, 5-hexadiene. L is a neutral ligand, which can relatively easily be exchanged with other ligands, and is for instance a nitrile or a co-ordinating solvent, in particular acetonitrile, dimethylsulphoxide (DMSO) , methanol, water, tetrahydrofuran, dimethylformamide, pyridine and N-methylpyrrolidinone.
Examples of suitable transition metal compounds are:
[Ir(COD)Cl]2, [Ir(CO)2Cl]n, [IrCl (CO) 3]n, [Ir(Acac) (COD)], [Ir (NBD) Cl] 2, [Ir (COD) (C6H6) ] +BF4 ", [ (CF3C(0)CHC(0)CF3)Ir(COE)2] , [Ir (CH3CN) 4] +BF4 " ,
[RuCl2(η6-benzene) ]2, [RuCl2 (η6-cymene) ] 2, [RuCl2(η6- mesitylene) ]2, [RuCl2 (η6-hexamethylbenzene) ] , [RuCl2(η6- 1,2,3, 4-tetramethylbenzene) ]2, [RuBr2 (η6-benzene) ]2, [Rul2(η6-benzene) ]2, trans- [RuCl2 (DMSO) 4] , [RuCl2 (PPh3) 3] , [Rh(C6Hιo)Cl]2 (in which C6Hι0 = hexa-1, 5-diene) , [CoCl2] , [Rh(COD)Cl]2.
Most preferably, the transition metal compound is [Ir (COD) Cl] 2. Very good results have been obtained with this. The invention also relates to a process for the preparation of the catalyst according to the invention as described above, which involves the addition to a catalyst precursor, which contains the transition metal, an anion and a spectator ligand that is difficult to exchange, of a nitrogen-containing enantiomerically enriched ligand containing sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms. The catalyst can be prepared before it is used as an asymmetrical transfer hydrogenation catalyst or it can be formed in situ just before or during use, optionally in the presence of the reagents to be converted with the catalyst.
In a further embodiment, catalysts according to the invention can be made to be readily soluble in water or highly polar solvents . The catalysts of the invention can be rendered water-soluble by introducing water-soluble groups in the ligand, for instance, salts of carboxylic acids, salts of sulphonic acids and salts of phosphoric acids. Another possibility is the introduction of a trialkylammonium salt or a tetraalkylammonium salt in the ligand. A third group of substituents that can be introduced on the ligand are the neutral polar groups of which there may be various present in the molecule, such as alcohols and sulphoxides . Another way of rendering the catalyst water-soluble is to use bifunctional counter ions for the metal, for instance biscarboxylic acids, bisphosphates and bissulphonates . One of the two acid groups then serves as counter ion for the metal, while the other acid group is present as the salt of for instance sodium, potassium or lithium and imparts water solubility. It is also possible to introduce water- soluble groups on the spectator ligand. The advantage of a water-soluble catalyst is that the transfer hydrogenation reaction can be carried out in a two-phase system, for instance a (more) polar aqueous phase and a (less polar) organic phase such as water/organic solvent, with the catalyst and the reducing agent being in the aqueous phase and the starting material and the product in the organic phase. As a result, the catalyst can very simply be separated from the product. A mixture of triethylamine and formic acid can also be chosen as the more polar phase. An example is the reduction of ketones in a two-phase system, with the more polar phase comprising an azeotropic mixture of triethylamine and formic acid, and the less polar phase comprising the ketone and the alcohol formed therefrom, optionally in the presence of a non-water-miscible solvent. At the end of the reaction the product can simply be separated by phase separation and the more polar phase can, after addition of extra formic acid, be reused in the reduction of a new batch of ketone. Another example of a more polar phase is ionic liquids. Examples of these are salts of imidazole such as l-hexyl-3-methyl-imidazolium salts or N-alkyl pyridinium salts. These compounds are characterized by the fact that they are liquids at room temperature.
The invention also relates to a process for the preparation of an enantiomerically enriched compound from the corresponding prochiral compound via catalytic asymmetrical transfer hydrogenation in the presence of a hydrogen donor and the catalyst according to the invention as described above. The process can for instance very suitably be used in the preparation of enantiomerically enriched alcohols, hydrazines or amines starting from the corresponding prochiral ketones and, respectively, hydrazones, oxime derivatives or imines .
The catalysts of the invention can also advantageously be used for the kinetic resolution of carbonyl compounds - e.g. ketones or aldehydes - or imines, oximes or hydrazones which already contain at least one chiral centre elsewhere in the molecule and are present in racemic form. Reduction of the carbonyl compounds, imines, oximes or hydrazones then most preferably takes place only in one of the two enantiomeric forms. By terminating the reaction when approximately 50% conversion is achieved, the ketone (aldehyde, imine, oxime, hydrazone) can be recovered substantially in the one enantiomeric form; the other enantiomer has then substantially been converted to the corresponding alcohol, amine or hydrazine.
The catalysts of the invention can also be advantageously used for the kinetic resolution of a racemic alcohol by oxidation in the presence of the catalyst according to the invention. In this reaction it is higly preferred for only one of the enantiomers of the alcohol to be oxidised, so that after about 50% conversion a mixture has formed of the alcohol, consisting substantially of a single enantiomer, and the corresponding ketone, which has been formed from the other enantiomer. Suitable oxidants for this are ketones or aldehydes, for instance acetone or chloral (hydrate) . The catalysts of the invention can also be advantageously used for the desymmetrization of meso diols by oxidation in the presence of the catalyst according to the invention. In this reaction the meso diol is oxidised to a hydroxy ketone in a stereoselective manner such that the product hydroxy ketone consists substantially of a single enantiomer. The catalysts of the invention can also in principle be advantageously used for the preparation of a ketone in an enantiomeric excess from a racemic alcohol which contains a further chiral racemic centre that is not bound to the OH group by oxidation in the presence of the catalyst according to the invention so that after about 50% conversion a mixture has formed of the enantiomerically enriched ketone (formed substantially from one of the two absolute configurations at the chiral centre not bound to the OH group) and two enantiomerically enriched diastereomers of the alcohol, consisting substantially of the other absolute configuration at the chiral centre not bound to the OH group. However, if the chiral centre that is not bound to the OH group is enantiomerically enriched, then oxidation by the catalyst according to the invention yields a ketone which is enantiomerically enriched. However, the catalyst according to the invention can in principle be used to selectively oxidise one of the two diastereomers which are epimeric at the carbon bound to the OH group, so that after about 50% conversion a mixture has formed of the enantiomerically enriched ketone (formed substantially from one of the two enantiomerically enriched epimers) and the diastereomerically enriched alcohol (consisting substantially of the other enantiomerically enriched epimer) .
The invention also relates to a process for the preparation of an enantiomerically enriched compound with two or more chiral, non racemic centres in which a chiral, non racemic ketone, imine, oxime or hydrazone is reduced in the presence of a catalyst according to the invention. In this process the ketone (imine, oxime, hydrazone) is fully reduced to a compound with substantially only one relative configuration between the existing chiral, non racemic centre (s) and the new chiral, non racemic centre.
As prochiral compounds use can for instance be made of prochiral ketones of the general formula:
Figure imgf000015_0001
where R and R' are not the same and each independently represent an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms or together they form a ring along with the carbonyl C-atom to which they are bound, it being possible for R and R' to also contain one or more heteroatoms or functional groups. Suitable examples of prochiral ketones include acetophenone, 1- acetonaphthone, 2-acetonaphthone, 3-quinuclidinone, 2- methoxycyclohexanone, l-phenyl-2-butanone, benzyl- isopropyl ketone, benzyl acetone, cyclohexyl-methyl ketone, tert-butyl-methyl ketone, tert-butyl-phenyl ketone, isopropyl-phenyl ketone, ethyl- (n-propyl) ketone, o, m or p-methoxy acetophenone, o, m or p- (fluoro-, chloro-, bromo- or iodo-) acetophenone, o, m or p-cyano-acetophenone, o, m or p-nitro-acetophenone, 2-acetylfluorene, acetylferrocene, 2-acetylthiophene, 3- acetylthiophene, 2-acetylpyrrole, 3-acetylpyrrole, 2- acetylfuran, 3-acetylfuran, 1-indanone,
2-hydroxy-1-indanone, 1-tetralone, p-methoxyphenyl-p' - cyanophenylbenzophenone, cyclopropyl- (4-methoxyphenyl) ketone, 2-acetylpyridine, 3-acetylpyridine, 4- acetylpyridine, acetylpyrazine; prochiral imines of the general formula:
Figure imgf000015_0002
where R, R' and R" for instance each independently represent an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms or form a ring together with the atoms to which they are bound, it being possible for R , R' and R" to also contain one or more heteroatoms and functional groups, and R" may in addition be a group to be split off. Suitable prochiral imines may be prepared from the above-described ketones and an alkyl amine, aralkyl amine or aryl amine or an amino acid derivative, for instance an amino acid amide, an amino acid ester, a peptide or a polypeptide. Examples of suitable alkyl amines, aralkyl amines and aryl amines are a benzyl amine, for instance benzyl amine, or an o-, m- or p- substituted benzyl amine, an α-alkyl benzyl amine, a naphthyl amine, for instance naphthyl amine, a l-,2-,3- ,4-, 6-, 7-, 8- or 9-substituted naphthyl amine and a 1-(1- naphthyl ) alkyl amine or a 1- (2-naphthyl) alkyl amine. Suitable imines are for instance N- (2-ethyl-6- methylphenyl ) -1-methoxy-acetonimine, 5, 6-difluoro-2- methyl-1, 4-benzoxazine, 2-cyano-l-pyrroline, 2- ethyoxycarbonyl-1-pyrroline, 2-phenyl-l-pyrroline, 2- phenyl-3 , 4, 5, 6-tetrahydropyridine and 3 , 4-dihydro-6, 7- dimethoxy-1-methyl-isoquinoline; oximes or hydrazones of the general formula
Figure imgf000016_0001
where
X contains a heteroatom and represents NH, NR or 0, for instance, with R representing an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms .
Ri and R2 each independently represent an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms, or form a ring with each other or with R3 and the atoms to which they are bound, which groups may also contain one or more heteroatoms and/or functional groups. - in the case of an oxime or oxime ether, R3 is H or an alkyl, aryl, aralkyl, alkenyl or alkynyl group with 1-20 C-atoms, which groups may also contain one or more heteroatoms and/or functional groups; and in the case of a hydrazone it is H, an alkyl, aryl, alkenyl, alkynyl, acyl, phosphonyl or sulphonyl group with 0-20 C-atoms, which groups may also contain one or more heteroatoms and/or functiona1 groups .
The process according to the invention is carried out in the presence of one or more hydrogen donors, which in the framework of this invention are understood to mean compounds that can in any way transfer hydrogen to the substrate, for instance thermally or catalytically . Examples of suitable hydrogen donors that can be used are aliphatic or aromatic alcohols, in particular secondary alcohols with 1-10 C-atoms, for instance 2-propanol and cyclohexanol, acids, for instance formic acid, H3P02, H3P03 and salts thereof, partially unsaturated hydrocarbons, partially unsaturated heterocyclic compounds, hydroquinone or reducing sugars. Preferably, 2-propanol or formic acid is used. The molar ratio of substrate to hydrogen donor preferably lies between 1:1 and 1:100.
In the asymmetrical transfer hydrogenation use is preferably made of a molar ratio of metal present in the transition metal compound to substrate of between 1:10 and 1:1,000,000, in particular between 1:100 en 1:100,000. The temperature at which the asymmetrical transfer hydrogenation is carried out in general is a compromise between the reaction velocity on the one hand and the degree of racemisation on the other, and preferably lies between -20 and 100°C, in particular between 0 and 60°C. The asymmetrical transfer hydrogenation can in principle be carried out in an oxygen-containing atmosphere; preferably, however, the asymmetrical transfer hydrogenation is carried out in an inert atmosphere, for instance under nitrogen. As solvent in principle any solvent can be used that is inert in the reaction mixture. In a preferred embodiment a solvent is used that also serves as hydrogen donor, for instance 2-propanol. If the asymmetrical transfer hydrogenation is carried out in water, with a 2-phase system being formed, preferably a water-soluble catalyst is used. The catalyst for the asymmetrical transfer hydrogenation can if desired be activated by hydrogenation with hydrogen or by treatment with a base, for instance an alkali (alkaline earth) compound, for instance an alkali (alkaline earth) hydroxide, an alkali (alkaline earth) carboxylate or an alkali (alkaline earth) alkoxide with 1-20 C-atoms, as alkali metal for instance Li, Na or K being used and as alkaline earth metal for instance Mg or Ca. Suitable bases are for instance sodium hydroxide, potassium hydroxide, potassium-t-butoxide and magnesium methoxide. In the preparation of the catalyst the molar ratio of metal to the enantiomerically enriched ligand is preferably chosen to be between 2:1 and 1:10, preferably between 1 : 1 and 1:6.
As the hydrogen donor in the process according to the invention, use is advantageously made of a hydrogen donor that effects irreversible transfer hydrogenation. An example of such a hydrogen donor is formic acid or a formic acid salt, preferably in combination with triethylamine. In this case the formic acid decomposes and carbon dioxide gas is formed in the transfer hydrogenation reaction and, this being outside the reaction equilibrium, the reaction runs to completion. With these hydrogen donors that effect irreversible transfer hydrogenation, a higher substrate concentration can be chosen compared to an alcohol such as isopropanol.
Preferably, the concentration of prochiral compound is at least 0.2, more preferably at least 0.5 and even more preferably at least 0.7 mol per litre of the hydrogen donor. Under these conditions the catalyst according to the invention has been found to be stable, in particular when iridium is used as the transition metal .
The invention will be elucidated with reference to the examples, without however being restricted thereto.
Examples I up to and including XIX and comparative experiments Cl up to and including C3
Various catalysts according to the invention were prepared and tested for their enantioselectivity and conversion under different conditions, the ligands, the hydrogen donor, the catalyst precursor and the prochiral compound being varied. In comparative experiments Cl up to and including C3 , with a catalyst according to the invention with a very good performance, the sulphur in the enantiomerically enriched ligand (ligand 6) was replaced with oxygen (ligand 7) . In all experiments use was invariably made of the standard set of conditions as defined below. The variations in these standard conditions used are given with the results below Table 2.
The reaction with formic acid as hydrogen donor proceeds as follows: a solution of [IrCl(COD)]2 (0.01 mmol, 6.7 mg) as catalyst precursor (COD is cyclooctadiene) , 0.05 mmol ligand and 4 mmol acetophenone as substrate was heated at 65°C for 30 min under argon. The argon supply was stopped and 3 ml of a 5/2 azeotropic mixture of formic acid (as hydrogen donor) and triethylamine was added in air. The reaction proceeded at 60 °C in an open vessel for the indicated time.
The reaction with 2-propanol as hydrogen donor proceeds as follows: the solution of [IrCl(COD)]2 (0.01 mmol, 6.7 mg) , 0.05 mmol of the ligand and 5 ml 2- propanol were heated at 80°C for 30 min. After cooling to room temperature the mixture was diluted with 33.75 ml 2-propanol and 4 mmol acetophenone and t-BuOK (1.25 ml, 0.1M in propan-2-ol, 0.125 mmol) . The reaction was carried out at room temperature under argon for the indicated time.
The enantiomeric excess of the 1-phenethyl alcohol formed was determined by means of capillary GLC using a Carlo Erba GC 6000 Vega 2 with a 25 m Cyclosil-B (chiral) column. The enantiomeric excess is defined as ( ( [R] - [S]) / ([R] + [S]))*100%, where [R] and [S] are the concentrations of the R enantiomer and the S enantiomer. The conversion, expressed as the percentage of acetophenone converted in one hour, was determined by means of GLC. The optical rotation was determined using a Perkin-Elmer 241 automatic polarimeter.
The ligands used are presented in Table 1 (Bn is benzyl, iPr is isopropyl, Ph is phenyl) and described below. The results of the examples according to the invention and the comparative experiments are shown in Table 2.
S-Benzyl- {R) -cysteinol sulfoxide (3) Hydrogen peroxide (30% in water, 5 mmol,
0.51 ml) was added to S-benzyl- (i?) -cysteinol in methanol (1 g, 5 mmol), at -70 °C. The reaction mixture was slowly warmed to room temperature and stirred overnight. It was evaporated to dryness to yield a white solid (100%) . The two diastereomers were separated by repeated crystallisation from ethanol.
S-Benzyl- (R) -cysteinol (S) -sulfoxide (3(S, R) )
M.p.: 130-133 °C. IR (KBr) : V (cm-1) = 3329, 3270, 3108, 2925, 1600, 1495, 1454, 1096, 1071, 1029, 985, 700. !H MR (CD3OD) : δ = 2.73 (1H, dd, J = 7.0 Hz, 13.2 Hz, S(0)CH2), 2.96 (1H, dd, J = 6.0 Hz, 13.2 Hz, S(0)Cff2), 3.31 (1H, m, CH) , 3.54 (1H, d, J = 5.4 Hz, CH2-OH) , 3.55 (1H, d, J = 5.4 Hz, CH2-OH) , 4.05 (1H, d, J = 13.0, Ph-CH2), 4.22 (1H, d, J = 13.0, Ph-
CH2), 7.37 (5H, s, ζH5 ) . 13C NMR (CDCI3): δ = 49.48 (CH), 54.38, 58.60, 65.25 (3 CΗ2 ) , 128.62, 129.00, 130.20 (CHarom), 129.31 (Cq). HRMS (FAB+) : m/z calcd for CιoHιg 02S [M+H]+: 214.0902. Found: 214.0910. Anal. Calcd for C10H15NO2S: C, 56.31; H, 7.09; N, 6.57; S, 15.03. Found: C, 55.97; H, 7.01; N, 6.48; S, 14.62. [α]20 D = -46° (c = 0.51, EtOH) .
S-Benzyl- (R) -cysteinol (R) -sulfoxide (3(-R,iR))
M.p.: 128-129 °C. IR (KBr) : V (cm-1) = 3311, 3274, 3186, 2886, 1611, 1494, 1453, 1364, 1069, 1025, 1002, 992, 762, 689. ^ NMR (CD3OD) : δ = 2.74 (IH, dd, J = 9.6 Hz, 13.2 Hz, S(0)CH2), 2.85 (IH, dd, J = 3.6 Hz, 13.2 Hz, S(0)CH ), 3.28 (IH, m, CH) , 3.52 (IH, dd, J = 5.7 Hz, J = 10.9 Hz, CH2-OH) , 3.55 (IH, dd, J" = 5.4 Hz, J = 13.9 Hz, CH2-OH) , 4.07 (IH, d, J = 12.9, Ph-CH2), 4.19 (IH, d, J = 13.0, Ph-CH2 ) , 7.37
(5H, s, C6H5) . 13C NMR (CDCI3): δ = 48.03 (CH) , 55.26,
58.35, 66.07 (3 CH2 ) , 128.60, 129.03, 130.20 (CHarom) ,
129.51 (Cq) . HRMS (FAB+) : m/z calcd for CιoHιgN02S [M+H]+: 214.0902. Found: 214.0904. Anal. Calcd for C10Hι5NO2S: C, 56.31; H, 7.09; N, 6.57; S, 15.03.
Found: C, 55.85; H, 7.07; N, 6.37, S, 14.98. [α]20 D = +16° (c = 0.9, EtOH) .
{ IR, 2S) -2-Amino-l-phenyl-l-isopropylthio-propane (4)
A slight excess of isopropylmercaptan was added to a solution of ( 2S, 35) -3-methyl-2- phenylaziridine in methanol. The solution was stirred overnight at 65 °C. The solvent and the excess isopropylmercaptan were removed under reduced pressure. The product was obtained as a light yellow oil after column chromatography (silica gel 60, eluent : dichloromethane / 5% methanol, Rf-value: 0.40). Yield:
32%. IR (neat): v (cm'1) = 3363, 3060, 3026, 2962, 2925, 1452, 734, 701. NMR (CDCI3): δ = 1.12 (3H, d, J = 6.8 Hz, CH3) , 1.17 (3H, d, J = 6.4 Hz, CH3) , 1.22 (3H, d, J = 6.5 Hz, CH3) , 1.32 (2H, bs , NH2 ) , 2.54, (IH, m, CH(CH3)2) , 3.24 (IH, m, (CH3)CH) , 3.74 (IH, d,
J = 6.6 Hz, (Ph)CH), 7.17-7.50 (m, 5 H, CeH5). 13C NMR (CDCI3): δ = 21.67, 23.28, 23.80 (3 CH3), 34.49, 51.69, 57.63 (3 CH) , 127.33, 128.52, 128.93 (CHarom) , 140.68 (Cq) . HRMS (FAB+) : m/z calcd for Cι2H 0NS [M+H]+: 210.1316. Found: 210.1315. [α]20 D = -151° (c = 0.84, CHCI3) .
(IR, 2S) -2-Amino-l-phenyl-l-benzylthio-propane (5) A slight excess of benzylmercaptan was added to a solution of (2S, 3S) -3-methyl-2- phenylaziridine in methanol. The solution was stirred overnight at 65 °C. The solvent was removed under reduced pressure . The product was obtained as a light yellow oil after column chromatography (silica gel 60, eluent: dichloromethane / methanol: 9/1, Rf-value:
0.38). Yield: 73%. IR (neat): V (cm"1) = 3367, 3060, 3028, 2964, 2924, 1600, 1492, 1452, 910, 735, 701. ^-H NMR (CDCI3) : δ = 1.12 (3H, d, J = 6.4 Hz, CH3 ) , 1.27 (2H, bs, NH2), 3.22, (IH, m, CH) , 3.36 (IH, d, J = 13.3 Hz, CH2), 3.52 (IH, d, J = 6.9 Hz, CH) , 3.53 (IH, d, J
= 13.3 Hz, CH2), 7.15-7.35 (m, 10 H, CeH5). 13C NMR (CDCI3): δ = 21.69 (CH3), 35.63 (CH2), 51.33, 58.06 (2 CH) , 127.10, 127.53, 128.54, 128.61, 129.13, 129.25 (CHarom), 138.36, 140.00 (2 Cq) . HRMS (FAB+) : m/z calcd for C16H20NS [M+H]+: 258.1316. Found: 258.1317. [α]20 D = -32° (c = 0.99, CHCI3) . ( IR, 2S) -2-Amino-l, 2-diphenyl-l-benzylthio-ethane (6)
A slight excess of benzylmercaptan was added to a solution of ( 2S, 3S) -2 , 3-diphenylaziridine in methanol. The reaction mixture was stirred for 3 days in refluxing methanol . The solvent was removed under reduced pressure. The product was obtained as a light yellow oil after column chromatography (silica gel 60, eluent : ethyl acetate / hexane: 1/1, Rf-value: 0.37). Yield: 38%. IR (neat): v (cm"1) = 3370, 3061,
3028, 2918, 1601, 1493, 1463, 735, 700. XH NMR (CDC13): δ = 1.55 (2H, bs, NH2), 3.28, (2H, d, J = 5.6 Hz, CH2 ) , 3.82 (IH, d, J = 8.1 Hz, CH) , 4.26 (IH, ά, J = 8.1 Hz, CH) , 7.08-7.30 (m, 15 H, CgH5) . 13C NMR (CDCI3): δ = 36.05 (CH2), 56.97, 60.96 (2 CH) , 127.12, 127.67, 127.75, 127.88, 128.43, 128.53, 128.72, 129.21 (CHarom), 138.02, 139.82, 142.92 (3 Cq) . HRMS (EI+) : m/z calcd for C2ιH 1NS [M] + : 319.1395. Found: 319.1399.
[α]20D = +110° (c = 0.62, CHCI3).
( IR, 2S) -2-Amino-l-phenyl-l- (2 ' -phenylethylthio) - propane ( 8 )
A slight excess of 2-phenylethylmercaptan was added to a solution of ( 2S, 3S) -3-methyl-2- phenylaziridine in methanol. The solution was stirred for three days at 65 °C. The solvent was removed under reduced pressure. The product was obtained as a colourless oil after column chromatography (silica gel 60, eluent: diethyl ether, Rf-value: 0.19). Yield: 35%. !H NMR (CDCI3) : δ = 1.19 (3H, d, J = 6.4 Hz, CH3 ) , 1.44 (2H, bs, NH2), 2.50, (2H, t, J = 7.3 Hz, CH2 ) , 2.68- 2.82 (2H, m, CH ), 3.18-3.31 (IH, m, (CH3)CH), 3.66 (IH, d, J = 7.4 Hz, (Ph)CH), 7.01-7.10 (2H, m, CHarom) , 7.16-7.31 (4H, m, CHarom) , 7.31-7.39 (4H, m, CHarom) .
13C NMR (CDCI3): δ = 21.59 (q, CH3), 32.68 (t, CH2 ) , 36.13 (t, CΑ2 ) , 51.26 (d, CH) , 58.70 (d, CH) , 126.21 (d, CHarom) , 127.35 (d, CHarom) , 128.32 (d, CHarom) , 128.42 (d, CHarom), 128.84 (d, CHarom) , 139.90 (s, Cq) , 140.44 (s, Cq) .
( IR, 2S) -2-Amino-1-phenyl-l-cyclohexylthio-propane (9)
A slight excess of cyclohexylmercaptan was added to a solution of ( 2S, 3S) -3-methyl-2- phenylaziridine in methanol. The solution was refluxed overnight . The solvent was removed under reduced pressure. The product was obtained as a colourless oil after column chromatography (silica gel 60, eluent: diethyl ether, Rf-value: 0.14). Yield: 41%. ^ NMR
(CDCI3) : δ = 1.15 (3H, d, J = 6.4 Hz, CH3) , 1.04-1.37
(6H, m, ζHn ) , 1.53 (2H, bs, NH ), 1.60-1.81 (3H, m, CeHn), 1.86-2.02 (IH, m, CgHn) , 2.24-2.43 (IH, m, C6H11>' 3.17-3.30 (IH, m, (CH3)CH), 3.77 (IH, d, J = 6.5 Hz, (Ph)CH), 7.19-7.41 (5H, m, CHarom) . 13C NMR (CDCI3): δ = 21.40 (q, CΗ3), 25.75 (t, CH2 ) , 25.96 (t, CH2), 33.38 (t, CH2), 33.81 (t, CH2 ) , 42.91 (d, CH) , 51.52 (d, CH) , 56.87 (d, CH) , 127.08 (d, CHarom) ,
128.29 (d, CHarom) , 128.69 (d, CHarom) , 140.69 (s, Cq) .
(IS, 2R) -2-Amino-l , 2-diphenyl-l- (2 ' -phenylethylthio) - ethane (10) A slight excess of 2-phenylethylmercaptan was added to a solution of ( 2R, 3R) -2 , 3- diphenylaziridine in methanol . The solution was refluxed for six days. The solvent was removed under reduced pressure. The product was obtained as a light yellow oil after column chromatography (silica gel 60, eluent: ethyl acetate / hexane: 1/1). Yield: 48%. ^-H
NMR (CDCI3): δ = 1.86 (2H, bs, NH2), 2.33, (2H, t, J =
7.4 Hz, CH2), 2.57-2.64 (2H, m, CH2 ) , 3.99 (IH, d, J =
8.5 Hz, CH) , 4.26 (IH, d, J = 8.3 Hz, CH) , 6.88-7.00 (4H, m, CHarom) , 7.11-7.25 (7H, , CHarom) , 7.24-7.37
(4H, m, CHarom) . 13C NMR (CDCI3): δ = 32.84 (t, CH2), 35.93 (t, CH2), 57.62 (d, CH) , 60.85 (d, CH) , 126.12 (d, CHarom), 127.34 (d, CHarom), 127.52 (d, CHarom) , 127.67 (d, CHarom), 128.24 (d, CHarom) , 128.38 (d, CHarom) , 128.47 (d, CHarom) , 128.86 (d, CHarom) , 139.57 (s, Cq) , 140.40 (s, Cq) , 142.64 (s, Cq) .
Table 1
Figure imgf000027_0001
Figure imgf000028_0001
1) formic acid / triethylamine used as hydrogen donor
2) 2-propanol used as hydrogen donor
3) substrate is 1-naphthyl-methyl ketone
4) substrate is phenyl-ethyl ketone
5) catalyst precursor is [Ru(p-Cy)Cl2] 2
6) catalyst precursor is [Rh(COD)Cl]2

Claims

1. Catalyst for asymmetrical transfer hydrogenation on the basis of a transition metal compound and a nitrogen-containing enantiomerically enriched ligand, characterized in that the transition metal is iridium, ruthenium, rhodium or cobalt and the enantiomerically enriched ligand contains sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms .
2. Catalyst according to claim 1, characterized in that the transition metal is iridium.
3. Catalyst according to claim 1 or claim 2, characterized in that the sulphur is bound to the nitrogen via two carbon atoms.
4. Catalyst according to any one of claims 1 - 3, characterized in that of the two or more carbon atoms that bind the sulphur to the nitrogen at least the carbon bound to the sulphur is chiral.
5. Catalyst according to any one of claims 1 - 4, characterized in that the enantiomerically enriched ligand has two or more chiral centres.
6. Catalyst according to claim 5, characterized in that the enantiomerically enriched ligand is a sulphoxide, one of the two or more chiral centres being the sulphur of the sulphoxide.
7. Catalyst according to claim 5, characterized in that the enantiomerically enriched ligand is a thioether in which the carbon atoms to which the thioether and the amino group are bound are both chiral .
8. Catalyst according to any one of claims 5 - 7, characterized in that the enantiomerically enriched ligand is a single diastereomer form.
9. Catalyst according to any one of claims 1 - 8, characterized in that the sulphur is substituted with .a substituted or non-substituted (hetero) aryl, (hetero) aralkyl, or alkyl group.
10. Catalyst according to any one of claims 1 - 9, characterized in that the enantiomerically enriched ligand is derived from enantiomerically enriched cysteine.
11. Catalyst according to any one of claims 1 - 9, characterized in that the enantiomerically enriched ligand is derived by reaction of an enantiomerically enriched aziridine converted with a thiol compound.
12. Process for the preparation of a catalyst according to any one of claims 1-11, characterized in that it involves the addition to a catalyst precursor, which contains the transition metal, an anion and a spectator ligand that is difficult to exchange, of a nitrogen-containing enantiomerically enriched ligand which contains sulphur in the form of a thioether or a sulphoxide, the sulphur being bound to the nitrogen via two or more carbon atoms.
13. Process for the preparation of an enantiomerically enriched compound from the corresponding prochiral compound via catalytic asymmetrical transfer hydrogenation in the presence of a catalyst and a hydrogen donor, characterized in that use is made of a catalyst according to any one of claims 1-11.
14. Process according to claim 13, in which a prochiral ketone, imine, oxime or hydrazone is used as the prochiral compound.
15. Process for the kinetic resolution of a chiral, racemic ketone, aldehyde, imine, oxime or hydrazone, in which one enantiomer of the chiral, racemic ketone, aldehyde, imine, oxime or hydrazone is stereoselectively reduced in the presence of a catalyst according to any one of claims 1-11.
16. Process for the preparation of an enantiomerically enriched compound with two or more chiral centres in which a chiral, non racemic ketone, imine, oxime or hydrazone is diastereomerically reduced in the presence of a catalyst according to any one of claims 1-11.
17. Process for the kinetic resolution of a racemic alcohol by preferential oxidation of one of the enantiomers of the alcohol in the presence of the catalyst according to any one of claims 1-11.
18. Process for the preparation of a hydroxy ketone in an enantiomeric excess by oxidation of a meso diol in the presence of the catalyst according to any one of claims 1-11.
19. Process for the preparation of a ketone and/or an alcohol in an enantiomeric excess from the corresponding racemic alcohol that contains a further chiral centre, which is not directly bound to the OH group, by oxidation in the presence of the catalyst according to any one of claims 1-11.
20. Process for the preparation of an enantiomerically enriched compound according to any one of claims 13-19, characterized in that isopropanol is used as the hydrogen donor .
21. Process for the preparation of an enantiomerically enriched compound according to any one of claims 13 - 16, characterized in that formic acid or a formic acid salt is used as the hydrogen donor.
22. Process for the preparation of an enantiomerically enriched compound according to claim 21, characterized in that the prochiral compound content is at least 0.2 mol per litre of the hydrogen donor .
PCT/NL2000/000701 1999-09-30 2000-09-29 Catalyst for asymmetric transfer hydrogenation WO2001023088A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU79721/00A AU7972100A (en) 1999-09-30 2000-09-29 Catalyst for asymmetric transfer hydrogenation
EP00970322A EP1227883A1 (en) 1999-09-30 2000-09-29 Catalyst for asymmetric transfer hydrogenation
JP2001526290A JP2003510180A (en) 1999-09-30 2000-09-29 Catalysts for asymmetric transfer hydrogenation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1013183 1999-09-30
NL1013183A NL1013183C2 (en) 1999-09-30 1999-09-30 Catalyst for asymmetric transfer hydrogenation.

Publications (1)

Publication Number Publication Date
WO2001023088A1 true WO2001023088A1 (en) 2001-04-05

Family

ID=19769971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2000/000701 WO2001023088A1 (en) 1999-09-30 2000-09-29 Catalyst for asymmetric transfer hydrogenation

Country Status (5)

Country Link
EP (1) EP1227883A1 (en)
JP (1) JP2003510180A (en)
AU (1) AU7972100A (en)
NL (1) NL1013183C2 (en)
WO (1) WO2001023088A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061826A1 (en) * 2002-01-24 2003-07-31 Dsm Ip Assets B.V. Process for preparing nonracemic chiral alcohols
WO2003061824A1 (en) * 2002-01-24 2003-07-31 Dsm Ip Assets B.V. Process for preparing nonracemic chiral alcohols
WO2003062180A1 (en) * 2002-01-24 2003-07-31 Dsm N.V. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7732365B2 (en) 2002-09-13 2010-06-08 Yale University Enantioselective amination and etherification
WO2012084810A1 (en) 2010-12-21 2012-06-28 Firmenich Sa Hydrogenation of esters or carbonyl groups with tetradentate amino/imino-thioether based ruthenium complexes
CN113186562A (en) * 2021-04-28 2021-07-30 安徽大学 Ir @ SC nanoparticle catalyst and preparation and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015522A2 (en) * 1979-03-06 1980-09-17 Studiengesellschaft Kohle mbH Process for the photochemical production of hydrogen from water
FR2591610A1 (en) * 1985-12-13 1987-06-19 Inst Francais Du Petrole Transition metal complexes prepared from tetracyanothiophene and tetracyanodithiine, and their use as catalysts for sweetening petroleum cuts in liquid and supported phase
US4962077A (en) * 1989-07-11 1990-10-09 Exxon Research And Engineering Company Transition metal tris-dithiolene and related complexes as precursors to active catalysts
WO1996020788A1 (en) * 1994-12-30 1996-07-11 Hoechst Aktiengesellschaft Epoxides produced by the oxidation of olefines with air or oxygen
US5914408A (en) * 1998-08-07 1999-06-22 Equistar Chemicals, Lp Olefin polymerization catalysts containing benzothiazole

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015522A2 (en) * 1979-03-06 1980-09-17 Studiengesellschaft Kohle mbH Process for the photochemical production of hydrogen from water
FR2591610A1 (en) * 1985-12-13 1987-06-19 Inst Francais Du Petrole Transition metal complexes prepared from tetracyanothiophene and tetracyanodithiine, and their use as catalysts for sweetening petroleum cuts in liquid and supported phase
US4962077A (en) * 1989-07-11 1990-10-09 Exxon Research And Engineering Company Transition metal tris-dithiolene and related complexes as precursors to active catalysts
WO1996020788A1 (en) * 1994-12-30 1996-07-11 Hoechst Aktiengesellschaft Epoxides produced by the oxidation of olefines with air or oxygen
US5914408A (en) * 1998-08-07 1999-06-22 Equistar Chemicals, Lp Olefin polymerization catalysts containing benzothiazole

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061826A1 (en) * 2002-01-24 2003-07-31 Dsm Ip Assets B.V. Process for preparing nonracemic chiral alcohols
WO2003061824A1 (en) * 2002-01-24 2003-07-31 Dsm Ip Assets B.V. Process for preparing nonracemic chiral alcohols
WO2003062180A1 (en) * 2002-01-24 2003-07-31 Dsm N.V. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
WO2003062181A1 (en) * 2002-01-24 2003-07-31 Dsm Pharmaceuticals, Inc. PROCESS FOR THE PREPARATION OF NONRACEMIC SYN-1-(4-HYDROXY-PHENYL)-2-(4-HYDROXY-4-PHENYL.PIPERIDIN-1Yl)-1-PROPANOL COMPOUNDS
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US6806378B2 (en) 2002-01-24 2004-10-19 Dsm N.V. Process for preparing nonracemic chiral alcohols
US7732365B2 (en) 2002-09-13 2010-06-08 Yale University Enantioselective amination and etherification
WO2012084810A1 (en) 2010-12-21 2012-06-28 Firmenich Sa Hydrogenation of esters or carbonyl groups with tetradentate amino/imino-thioether based ruthenium complexes
US8614345B2 (en) 2010-12-21 2013-12-24 Firmenich Sa Hydrogenation of esters or carbonyl groups with tetradentate amino/imino-thioether based ruthenium complexes
CN113186562A (en) * 2021-04-28 2021-07-30 安徽大学 Ir @ SC nanoparticle catalyst and preparation and application thereof

Also Published As

Publication number Publication date
NL1013183C2 (en) 2001-04-02
EP1227883A1 (en) 2002-08-07
JP2003510180A (en) 2003-03-18
AU7972100A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
CA2081315C (en) Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins
US8586498B2 (en) Homogeneous asymmetric hydrogenation catalyst
Belokon et al. Chiral salen–metal complexes as novel catalysts for the asymmetric synthesis of α-amino acids under phase transfer catalysis conditions
JP4153302B2 (en) Hydrogen transfer process and catalyst
US4965364A (en) Ligand-accelerated catalytic asymmetric dihydroxylation
Martins et al. Applications of N′-alkylated derivatives of TsDPEN in the asymmetric transfer hydrogenation of CO and CN bonds
CA1338314C (en) Ligand-accelerated catalytic asymmetric dihydroxylation
JP4194865B2 (en) Process for producing enantiomerically enriched arylaminopropanol
EP1227883A1 (en) Catalyst for asymmetric transfer hydrogenation
JP2019023181A (en) Improved process for preparation of chiral 3-amino-piperidins, as useful intermediates for preparation of tofacitinib
Busscher et al. Efficient preparation of an N-aryl β-amino acid via asymmetric hydrogenation and direct asymmetric reductive amination en route to Ezetimibe
US5227543A (en) Facilitation of turnover in the ADH by additives which catalyze the hydrolysis of the OS(VI) glycolate esters
US5516929A (en) Method for catalytic asymmetric dihydroxylation of olefins using heterocyclic chiral ligands
JP3924282B2 (en) Process for catalytic asymmetric dihydroxylation of olefins
EP0499376A1 (en) Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof
US5189200A (en) Process for the stereoselective transformation of a diol to an alcohol
US6274758B1 (en) Asymmetric hydrogenation of vinyl sulfones
US20030236429A1 (en) Process for the production of chiral compounds
EP1206438A1 (en) N-substituted norephedrine chiral derivatives, their preparation and their use for the synthesis of optically active functionalised compounds by hydrogen transfer
JPH08501781A (en) Stereoselective synthesis of 3-substituted 2-sulfonylmethylpropionic acids and intermediates
AU2007330711B2 (en) Method for the synthesis of N-[3-[(2-methoxyphenyl)sulfanyl]-2- methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine
WO2000010985A1 (en) Enantioselective chiral sulphide catalysts and a method for the manufacture thereof
HU180440B (en) New process for producing 2-carbalkoxy-methyl-3-ethyl-9,10-dimethoxy-1,2,3,6,7-hexahydro-11ah-benzo-bracket-a-bracket closed-quinolisine derivatives
ZA200205878B (en) Asymmetric synthesis of pregabalin.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000970322

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10089213

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 526290

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000970322

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000970322

Country of ref document: EP